All In Biotech

Drug Trial Radar · NCT00517712

Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

Molecular Remission With Arsenic Trioxide in Acute Promyelocytic Leukemia: Indian APL Study Group - IAPLSG

Last checked: Nov 20, 2026Latest source record: Aug 17, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

400

Planned (sponsor's estimate)

Start

Jun 2004

Primary completion

Not stated

Study completion Jul 2009

Sponsor

Lead sponsor
Christian Medical College, Vellore, IndiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Science and Technology, India
First posted
Aug 17, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There is very limited data on the use of arsenic trioxide in newly diagnosed patients with acute promyelocytic leukemia. The use of arsenic trioxide was limited to relapsed patients mainly because of the superior efficacy of ATRA as primary therapy for newly diagnosed APML. Though the early study by Niu et al showed 72% remission rates in 11 newly diagnosed patients, the role of arsenic trioxide as primary therapy was limited by the hepatic toxicity seen in this study. Studies from our centre have shown remission rates of 70-75% in newly diagnosed patients with acute promyelocytic leukemia. There was no major toxicity seen related to the administration of arsenic trioxide. Follow up data on these patients continue to show long term remission rates above 70%. These remission rates are similar to the data available in patients with acute promyelocytic leukemia treated with ATRA. Lu et al studied 19 patients treated with oral arsenic (Tetra-arsenic tetra-sulfide) wherein 84% achieved hematological remission with disease free survival of 76% at 3 years. Studies from other groups using arsenic trioxide alone or in combination with ATRA have shown similar remission rates. Arsenic trioxide as primary therapy for patients with newly diagnosed acute promyelocytic leukemia is a very attractive treatment option for developing countries mainly because of the low cost involved along with the favorable toxicity profile. However long term remission data is still not available and the ideal course and duration of treatment still needs to be defined. This multi-center study aims to further clarify the efficacy of this agent in the treatment of newly diagnosed cases of acute promyelocytic leukemia and to study the optimal maintenance regimen.

Conditions

  • Acute Promyelocytic Leukemia

Interventions

  • Single agent arsenic trioxideDrug

    duration of maintenance therapy, 6 months versus 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measure complete hematological remission rateTime frame: 60 days
  2. Measure complete molecular remission rateTime frame: 3 months
  3. Measure duration of responseTime frame: 5 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Kidwai Memorial Institute of Oncology

    Bangalore, Karnataka, India · Not yet recruiting

  • St. Johns Hospital

    Bangalore, Karnataka, India · Recruiting

  • Regional Cancer Center

    Trivandrum, Kerala, India · Recruiting

  • Prince Aly Khan Hospital

    Mumbai, Maharashtra, India · Not yet recruiting

  • KEM Hospital

    Mumbai, Maharashtra, India · Recruiting

  • Tata Memorial Hospital

    Mumbai, Maharashtra, India · Recruiting

  • Sahyadri Speciality Hospital

    Pune, Maharashtra, India · Recruiting

  • Institute Rotary Cancer Hospital

    New Delhi, New Delhi, India · Recruiting

  • Netaji Subhash Chandra Bose Cancer Research Institute

    Kolkata, West Bengal, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.